Steve Couldwell, chief executive of (), caught up with Proactive's Andrew Scott to discuss the group's interim 2018 results.
In the six months to the end of June they inked distribution agreements with Arthrex and ARMS Medical of the US and Pennine Healthcare here in the UK.
Another milestone was British regulatory sign-off for the BioRinse portfolio, while manufacturing of DermaPure, the company’s wound care product, has been successfully transferred to the CellRight facility in Texas ahead of schedule.
Couldwell says they've identified a number of potential new commercial opportunities they are “actively pursuing”.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE